MoonLake Immunotherapeutics (MLTX) Interest & Investment Income (2021 - 2022)
MoonLake Immunotherapeutics (MLTX) recorded quarterly Interest & Investment Income of $8431.0 in Q1 2022, up 273.88% quarter-over-quarter from $2255.0 in Q4 2021, and down 52.67% on a YoY basis from $17815.0 in Q1 2021.
MoonLake Immunotherapeutics (MLTX) Interest & Investment Income (2021 - 2022) Analysis & Trends
MoonLake Immunotherapeutics' Interest & Investment Income history runs 2 years deep, the most recent figure standing at $8431.0 for Q1 2022.
- In Q1 2022, Interest & Investment Income fell 52.67% year-over-year to $8431.0; the TTM figure through Mar 2022 stood at $18307.0 (changed N/A YoY), while the FY2021 annual figure was $27691.0, up 85.63% from the prior year.
- Interest & Investment Income was $8431.0 for Q1 2022 at MoonLake Immunotherapeutics, up from $2255.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $17815.0 in Q1 2021 to a low of $1481.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 597,319.59 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -14.79 Mn |
| 10 | MoonLake Immunotherapeutics | 1.25 Bn | 888.66 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 8,431.00 |
| Dec 31, 2021 | 2,255.00 |
| Sep 30, 2021 | 1,481.00 |
| Jun 30, 2021 | 6,140.00 |
| Mar 31, 2021 | 17,815.00 |